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Objectives: a performance improvement in small-diameter bypass grafts remains a clinical objective. The purpose of the
present investigation was to evaluate the potential of enhancing the thromboresistance of ePTFE grafts using a bioactive
heparinized graft luminal surface in a canine model.
Material and Methods: this study investigated the utility of heparin immobilization onto expanded polytetrafluoro-
ethylene using Carmeda1 BioActive Surface technology (CBAS-ePTFE) as a means of improving vascular graft throm-
boresistance. Graft luminal surfaces were covered uniformly with the stably bound, end-point immobilized heparin.
Results: acute canine (5 greyhounds) interposition experiments comparing CBAS-ePTFE grafts to control ePTFE grafts
showed that CBAS-ePTFE grafts remained patent and had significantly greater thrombus-free luminal surface (p5 0.05).
In a chronic canine (16 greyhounds) interposition experiment, significantly improved patency (p5 0.05) was observed
with CBAS-ePTFE grafts compared to controls. Long-term in vivo heparin bioactivity was demonstrated on CBAS-ePTFE
grafts explanted between 1 and 12 weeks. On all CBAS-ePTFE grafts, heparin activity levels ranged from 15±25 pmol/cm2
and did not differ significantly (p4 0.05).
Discussion: these results support the conclusion that a stable, CBAS-ePTFE surface provides improved thromboresistance
and improved patency in canine interposition models. Maintenance of heparin catalytic activity on the graft surface in vivo
likely contributes to this outcome and holds promise for the utility of this graft surface for clinical applications.
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Introduction
Improved patency of synthetic vascular grafts has
been a sought-after clinical goal since their intro-
duction nearly four decades ago. Expanded poly-
tetrafluoroethylene (ePTFE) vascular grafts have
demonstrated a long history of good clinical perform-
ance as vascular conduits. While ePTFE grafts show
patency performance comparable to saphenous vein
in above-knee clinical applications,1±4 there continues
to be room for performance improvement in grafts
used for 6-mm diameter applications. In small-
diameter applications (56 mm diameter) such as
below-knee bypass, however, all prosthetic vascular
graft materials are less than desirable in terms of
performance relative to autologous vein. Much effort
has gone into development of prosthetic small-
diameter grafts; but, due to the complex interactions
of blood-biomaterial contact surfaces, a clinically
acceptable small-diameter graft has yet to be devel-
oped.5 Bypass graft failure generally occurs as a con-
sequence of thrombus deposition on the graft luminal
surface, anastomotic intimal hyperplasia, or progres-
sion of vascular disease.5 Although anastomotic
hyperplasia and disease progression are important
factors, reducing the propensity for acute thrombotic
failure by improving luminal-surface thromboresis-
tance has significant potential for improving clinical
performance of small-diameter grafts.
One potential strategy for reducing thrombogeni-
city of prosthetic materials is to bind heparin to the
surface.6 Heparin is a polysaccharide anticoagulant
with a long history of clinical use.7 Consequently, a
number of heparin coating technologies have been
developed based upon different heparin binding
modalities.6,8±11 Some of the ideal functional charac-
teristics of a heparinized graft include uniform
heparinization, retention of heparin on the graft sur-
face, and maintenance of heparin bioactivity. One of
the most clinically successful heparin technologies has
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been the Carmeda1 BioActive Surface (CBAS).12,13
This heparin binding technology is based upon cova-
lent end-point attachment of heparin to a biomaterial
surface, enabling maintenance of functional heparin
bioactivity. CBAS immobilization has been shown to
lower platelet deposition, decrease the inflammatory
response including complement activation in oxygen-
ator membranes and extracorporeal circuits,14±16 and
to reduce thrombogenicity in heart-assist devices17
and coronary stents.18±21
The purpose of the present investigation was to
evaluate the potential of enhancing the thromboresis-
tance of GORE-TEX1 Vascular Grafts using CBAS
technology to provide a bioactive heparinized graft
luminal surface. We investigated the hypothesis that
stable CBAS heparin immobilization on an ePTFE
vascular graft provides improved thromboresistance
relative to untreated ePTFE control grafts.
Materials and Methods
Graft materials
Control grafts were commercially available ePTFE
grafts (GORE-TEX1 Vascular Grafts, W. L. Gore &
Associates, Inc., Flagstaff, AZ, U.S.A.). Test grafts
were the same ePTFE grafts treated with immobilized
heparin, using the proprietary Carmeda BioActive
Surface technology, and are referred to as CBAS-
ePTFE grafts. This CBAS heparin immobilization
produces a surface microstructure having stable, cova-
lently bound heparin. The covalent end-point linkages
maintain the catalytic bioactivity of the antithrombin
(AT) sites of the bound heparin.13 Uniformity of
luminal surface heparinization was assessed with
toluidine blue staining. The graft microstructures
were assessed by Scanning Electron Microscopy (SEM).
Acute in vivo interposition
This study was conducted to compare the relative
thromboresistance of CBAS-ePTFE grafts to that of
control ePTFE grafts. Relative thromboresistances
were assessed by comparing percentages of throm-
bus-free luminal surface in an acute canine carotid
artery interposition model that shows a propensity
for luminal thrombus build-up, often resulting in
occlusion of control ePTFE grafts. Thrombotic propen-
sity was enhanced by using small-diameter (3 mm 
4 cm) grafts without antiplatelet or antithrombotic
agents. The hypothesis tested was that the bioactive
surface of CBAS-ePTFE grafts would inhibit thrombus
accumulation thereby yielding greater thrombus-free
luminal surface compared to untreated control ePTFE
grafts. Five pairs of grafts implanted in five adult
greyhounds were evaluated. This study, and all sub-
sequent in vivo studies, were reviewed and approved
by the Animal Care and Use Committee in accordance
with the Animal Welfare Act.
CBAS-ePTFE and control ePTFE grafts were rando-
mized to the left or right carotid arteries and inter-
posed via end-to-end anastomoses. Blood flow then
was restored for 2 h. At the end of the flow period,
grafts were excised and rinsed carefully with saline to
remove residual blood. Each then was carefully
opened longitudinally and photographed. Percent
thrombus-free luminal surfaces (%TFS) were com-
puted from luminal-surface thrombus areas and total
luminal surface areas measured from digital images of
the photographs using Bioquant software (BQ TCW95
V2.50.4; R&M Biometrics, Inc., Nashville, TN, U.S.A.).
Chronic in vivo patency
Chronic in vivo performance studies were conducted
in a small-diameter (3 mm 3 cm) canine carotid
interposition model to compare the chronic patency
performance of CBAS-ePTFE grafts to that of control
ePTFE grafts. The hypothesis that CBAS-ePTFE
grafts would have improved patency performance
compared to control ePTFE grafts was tested.
The experiment included 16 greyhounds, each of
which received bilateral end-to-end carotid interposi-
tions, one CBAS-ePTFE and one control ePTFE. To
model clinical pharmacology, daily aspirin (325 mg)
and dipyridamole (50 mg) were begun two days
prior to implant and continued throughout the dur-
ation of the study. Prior to cross clamping, animals
received intraoperative heparin (100 IU/kg) which
was not reversed. Weekly duplex ultrasound was
used to assess in vivo graft patency. Patencies of graft
pairs retrieved at postoperative intervals up to
180 days were compared.
In vivo heparin function
This study was conducted to assess in vivo duration of
heparin bioactivity on CBAS-ePTFE grafts. The
hypothesis that heparin bioactivity would persist
under chronic in vivo exposure to blood flow was
tested in a canine model. Twenty grafts (15 CBAS-
ePTFE and 5 control ePTFE) were implanted in ten
adult female greyhounds (BW4 28 kg). Each animal
received bilateral, side-to-side, 6 mm6 12 cm
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aorto-iliac bypasses. Five received bilateral CBAS-
ePTFE grafts and five received one CBAS-ePTFE
graft and one contralateral, negative control ePTFE
graft. Implant durations were 1, 2, 4, 8, and 12
weeks. Two dogs (grafts: ncbas 3; nctrl 1) were
implanted per time point. Beginning 48 h prior to
surgery, each animal received aspirin (81 mg) bid
which was continued, minus the day of surgery,
through the duration of the experiment. Prior to
cross clamping, animals received intraoperative hep-
arin (100 IU/kg) which was not reversed. At explant,
two representative 2 cm segments from each graft
were rinsed in isotonic saline, cleared of endogenous
heparin in buffered 0.6 M borate in 0.01 M NaCl
(pH 9), and rinsed again with deionized H2O. Sam-
ples then were assayed for luminal-surface heparin
activity measured as capacity to bind AT and
expressed as AT bound per unit surface area (pmol/
cm2) as described.22,23
Statistical analyses
Percent thrombus-free surface of acute in vivo inter-
position grafts were compared with a paired Student's
t-test.24 Chronic in vivo patencies were evaluated with
Kaplan±Meier life table analysis and compared with a
log-rank test.25 One-way analysis of variance (ANOVA)
was used to compare mean heparin activities on
postexplant graft samples from the in vivo heparin
function study.24
Results
Heparin uniformity and microstructure
Uniform CBAS heparin immobilization on the ePTFE
microstructure is illustrated by the stained CBAS-
ePTFE graft in Figure 1. The similarly treated control
ePTFE graft segment in Figure 1 is unstained. The
SEM surface appearance of the CBAS-ePTFE shows
the typical ePTFE node-fibril microstructure (Fig. 2),
thereby confirming that the ePTFE microarchitecture
is unaffected by the heparin immobilization. The
mechanical properties of the CBAS-immobilized
grafts (data not shown) also were comparable to pre-
viously published data on the control ePTFE grafts.26
Acute interposition performance
In the five graft pairs, three control ePTFE grafts
occluded while all CBAS-ePTFE grafts remained
patent. In general, control ePTFE grafts exhibited
thrombus over substantial portions of their luminal
surfaces while CBAS-ePTFE grafts exhibited almost
no thrombus except for occasional, small accumula-
tions located mostly at the anastomoses. Control ePTFE
grafts also exhibited greater degrees of anastomotic
thrombus than were observed on CBAS-ePTFE grafts.
Luminal thrombus-free surface was significantly
greater ( p5 0.05) on the CBAS-ePTFE grafts
(%TFS 91.8+ 13.2) than on the contralateral control
ePTFE grafts (%TFS 33.2+ 32.4) (Fig. 3). A represen-
tative graft pair illustrating the difference in throm-
boresistance is shown in Figure 4.
Chronic patency performance
Data from all implanted grafts were analyzed includ-
ing those from one animal that did not receive
Fig. 1. Heparin coating uniformity demonstrated by toluidine blue
staining. (a) Control ePTFE graft showing no affinity for the tolui-
dine blue stain. (b) CBAS-ePTFE graft showing uniformly strong
affinity for the stain.
Fig. 2. Scanning electron micrograph of a CBAS-ePTFE graft luminal
surface showing typical node-fibril microstructure indicating that
the CBAS-immobilization does not alter the ePTFE microstructure.
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antiplatelet medications. After 3 days, 13 of 16 control
grafts had failed whereas all 16 CBAS-ePTFE grafts
were patent. At 180 days, patency results for CBAS-
ePTFE grafts were: five patent; four censored patent;
and seven failed. Patency results for control ePTFE
grafts were: one patent; two censored patent; and 13
failed. Compared to controls, CBAS-ePTFE grafts
showed significantly improved patency ( p5 0.05).
The patency results are summarized graphically in
Figure 5.
In vivo heparin function
Measurable heparin activity was detected on all ex-
planted CBAS-ePTFE grafts at each time point
examined out to 12 weeks. Mean activities on ex-
planted CBAS-ePTFE graft samples ranged from
24.7 7.9 pmol/cm2 measured at 2 weeks to
15.3 3.7 pmol/cm2 measured after 12 weeks
(Fig. 6). Differences between mean heparin activities
of explanted grafts at the various time points were
nonsignificant ( p4 0.05). Mean heparin activities on
control ePTFE grafts consistently were near or below
the lower detection limit of the assay (Fig. 6).
Discussion
Early graft thrombosis has remained an obstacle in the
development of a clinically acceptable, small-diameter
prosthetic vascular graft (56 mm diameter). Particu-
larly in low-flow, high-resistance situations, no
synthetic graft has shown sufficient resistance to
thrombus accumulation to enable routine adoption
in more demanding clinical applications such as
below-knee bypass. In below-knee applications,
Fig. 3. Mean percent thrombus-free surface of 3 mm-diameter
CBAS-ePTFE and control ePTFE grafts implanted acutely (2 h) as
paired bilateral carotid artery interpositions in the canine model.
Error bars 1 sd.
Fig. 4. Enhanced thromboresistance of a 3 mm-diameter CBAS-
ePTFE graft compared to a contralateral control ePTFE graft from
an acute (2 h) bilateral canine carotid artery interposition model.
(a) Control ePTFE graft showing thrombus accumulation along the
graft length. (b) CBAS-ePTFE graft showing minimal thrombus
accumulation.
Fig. 5. Kaplan±Meier summary graph of patencies of 3 mm CBAS-
ePTFE and control ePTFE grafts from canine carotid artery inter-
positions. CBAS-ePTFE (Ð); control ePTFE (----). Numbers above
the lines indicate grafts remaining at risk.
Fig. 6. Mean heparin activities (pmol/cm2) measured as AT binding
on replicate samples from CBAS-ePTFE and control ePTFE grafts
explanted from canines at 1, 2, 4, 8, and 12 weeks. Error bars
1 sd.
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synthetic vascular grafts are generally recognized to
have one-year patencies of around 60%.4 Approaches
to this clinical problem have included heparin bond-
ing to biomaterial surfaces. Heparinization of ePTFE
has been reported to inactivate thrombin; however,
early sheep model testing did not indicate any differ-
ence from untreated control grafts.27 Another heparin
modification technique using TDMAC (tridodecyl-
methylammonium) has been shown to reduce shed-
ding of microemboli from an ePTFE graft.28 Recently, a
heparin-bonded Dacron graft has been reported to
have 70% femoropopliteal patency at 1 year.29 Collec-
tively, these studies suggest the promise of a small-
diameter graft alternative based upon heparinization
technologies.
Important considerations of heparinization technol-
ogies are the bonding method and the long-term func-
tion of the heparin. The experimental CBAS-ePTFE
graft has the following key properties: uniform hep-
arinization as shown in Figure 1; and sustained in vivo
heparin bioactivity (Fig. 6). Previous attempts to hep-
arinize ePTFE did not incorporate these parameters
which could explain the mixed in vivo results obtained
to date.27,30
The findings from the present study demonstrate
the improved thromboresistance of the immobilized
heparin surface compared to an unmodified ePTFE
graft in vivo in canine carotid artery models. This
improvement was demonstrated both in acute and
chronic time frames. The greater thrombus-free sur-
face (Fig. 3) and obviously less thrombus accumula-
tion (Fig. 4) observed on 100% of the CBAS-ePTFE
grafts in the acute comparisons indicate that the
early blood interactions are affected by the presence
of bioactive heparin.
The evaluation of chronic graft patency as a meas-
ure of performance clearly demonstrated that a CBAS-
ePTFE graft surface improves patency compared to
untreated control ePTFE grafts in the canine carotid
interposition model. The patency difference that was
apparent early in the postimplant period, and was
sustained out to the 6-month end point (Fig. 5), likely
was attributable to inhibition of thrombus formation
conferred by the immobilized heparin.
It is recognized clinically that bypass graft failure
may be caused by thrombotic processes, anastomotic
hyperplasia, and/or disease progression. CBAS-
ePTFE appears especially to affect surface thrombotic
processes such that a greater proportion of CBAS-
ePTFE grafts remain patent during the initial high-
risk period for thrombotic failure. Consequently,
though secondary failure modalities such as anasto-
motic hyperplasia and disease progression still may
affect graft performance, the long-term patency rates
may be influenced positively by reduced thrombus
accumulation in the first several months of implant.
While there is no conclusive evidence regarding the
influence of CBAS-ePTFE on anastomotic hyperplasia,
it seems likely that sustained heparin activity may
reduce thrombus accumulation, thereby decreasing
the scaffold available for both midgraft and anastomo-
tic remodeling events. Additional studies will be
necessary to investigate this hypothesis.
The observed modulation of initial thrombus accu-
mulation is consistent with reports of reduced platelet
deposition on other CBAS-immobilized devices,
including stents and oxygenator membranes.12,15,31
Baboon ex vivo shunt testing of CBAS-treated coronary
stents has shown a significant decrease in platelet
deposition on heparinized stents compared to untreat-
ed control stents.31 Although the highly negative
charge associated with heparin may possibly explain
this phenomenon, the decrease was correlated speci-
fically with the immobilized high AT-affinity heparin
fraction. In addition, significantly reduced platelet
deposition also was correlated with heparin activity
as low as 7 pmol/cm2.31 In the present study, under
sustained exposure to blood constituents, heparin
activities persisted in vivo for 3 months at levels
between 15 and 25 pmol/cm2, well above the activity
shown to reduce platelet deposition on stents. Sus-
tained AT binding is consistent with previous studies
demonstrating maintenance of heparin activity for
4 months in porcine aortae,32 and for upwards of
2 months clinically on the Berlin Heart Assist Device.19
The improved performance of CBAS-ePTFE may
derive from both the stability of the heparin surface
and its sustained potential to bind AT in vivo (Fig. 6).
The precise mechanism at work on the CBAS-ePTFE
graft cannot fully be explained by the present study. It
seems likely though, that long-term maintenance of
active heparin on the ePTFE surface influences not
only the extrinsic, platelet-mediated pathways,
but also the intrinsic coagulation cascade. CBAS-
immobilized heparin previously has been shown to
block Factor XII initiation of the coagulation cascade,33
catalyze the rate of inactivation of thrombin by antith-
rombin effectively blocking conversion of fibrinogen
to fibrin,3 and improve resistance of synthetic surfaces
to platelet deposition.34 Furthermore, the heparin sur-
face also is known to influence initial protein depos-
ition on various biomaterials;35 thus, it also is likely
that the heparin-modified ePTFE surface is more
hemocompatible due to its influence on protein
adsorption during initial blood contacting events.31
Long-term clinical experience with CBAS-coated
coronary stents has demonstrated that use of these
stents effectively minimizes subacute thrombosis,20
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reduces major adverse cardiac events compared to
primary PTCA,19 and can result in improved sus-
tained patency.21 The results from the present study
are consistent with the hypotheses that CBAS-ePTFE
is more thromboresistant than untreated control
ePTFE and a CBAS-ePTFE surface improves short-
term and long-term graft patency in the canine arterial
interposition model. Further, the data illustrating
sustained heparin activity on the CBAS-ePTFE graft
surface in vivo support the inference that improved
thromboresistance results from stable CBAS heparin
immobilization. Given these findings and the exten-
sive clinical experience to date with CBAS-treated
medical devices, CBAS-ePTFE appears to hold prom-
ise for improved prosthetic graft performance in
vascular reconstructions.
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